Aether Catalyst Solutions, Inc. Announces Options Grants
Get Alerts ATHR Hot Sheet
Join SI Premium – FREE
Burnaby, British Columbia--(Newsfile Corp. - November 4, 2022) - Aether Catalyst Solutions, Inc. (CSE: ATHR) (FSE: 2QZ) ("ATHR" or the "Company") announces that it has granted 350,000 incentive stock options to employees. The incentive stock options have an exercise price of $0.10 per share, are valid for a 3 year period from the date of grant, and are subject to regulatory approval.
The Company's Stock Option Plan allows for the issuance of up to 10% of issued and outstanding share capital in the form of incentive stock options. As the result of the above grants, the company has 2,500,000 options issued, representing 5.0% of the issued and outstanding share capital.
ABOUT THE COMPANY:
Aether Catalyst Solutions, Inc., a clean air company, is focused on providing an order of magnitude cost reduction in automotive catalytic converter catalyst, while meeting, or exceeding government emission standards. Aether is working to quickly advance its technology through rapid screening of new material combinations. While Aether's primary focus has been automotive applications, the company is also developing catalysts to address small motors emissions - a significant contributor to urban air pollution.
FOR FURTHER INFORMATION PLEASE CONTACT:
Aether Catalyst Solutions, Inc.
Paul Woodward
President
Tel: 604 690-3797
http://www.aethercatalyst.com
The Canadian Securities Exchange ("CSE") or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this management prepared news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143180
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICAC Commissioner attends first IAACA European regional anti-corruption conference in Hungary
- Idaho Copper Corporation Announces Pricing of $18 Million Public Offering and NYSE American Listing
- Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
Create E-mail Alert Related Categories
Newsfile, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share